Global Fallopian Tube Cancer Market - Segmented by Therapy Type, and Geography - Growth, Trends, and Forecast (2019 - 2024)

Global Fallopian Tube Cancer Market - Segmented by Therapy Type, and Geography - Growth, Trends, and Forecast (2019 - 2024)

Purchase Report

The global fallopian tube cancer market is expected to register a CAGR of 5.2%, during the forecast period, (2018-2023). North America dominates the market, due to high healthcare expenditure in the region.

Increasing Health Care Expenditure          

There are several governments’ initiatives in developed nations all over the world to provide insurance to cancer patients, which allow them to opt for expensive surgeries and therapies involved in the treatment. This is owing to the fact that the number of cancer cases is increasing rapidly. According to a survey in 2017, about 609,640 Americans are expected to die of cancer that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. The increasing government intervention by increasing healthcare expenditure, for insuring cancer patients will boost the market growth heavily in the forecast period. Also, the rising awareness about this type of cancer may act as a major driver for this market.

Adverse Side Effects of Treatment and Toxicity of Drugs

Because many targeted drugs are still quite new, it’s hard to say how long you can expect side effects to last. We do know that some of the side effects from standard chemo drugs can last a lifetime, such as when the drug causes long-term damage to the heart, lungs, kidneys, or reproductive organs. These side effects along with the high costs of treatment may hinder many patients to seek proper treatment. This, in turn, will affect the overall growth of this market.

North America to Dominate the Market

North America dominates the global fallopian tube cancer market, owing to high incidence of cancer and its early diagnosis due to availability of advanced technology, and growing popularity of non-invasive radiation therapies for cancer in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high incidence of cancer diseases, less stringent regulatory scenario, and presence of huge population base.


Key Developments in the Market

  • March 2017: The U.S. Food and Drug Administration approved niraparib (ZEJULA) of Tesaro, Inc., a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

Major Players: Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this Report

  • Current and future global fallopian tube cancer market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

  • This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

1. Table of Contents

2. Introduction

                2.1 Market Definition

3. Research Methodology

4. Executive Summary

5. Key Inferences

6. Market Overview

                6.1 Current Market Scenario

                6.2 Porter's Five Forces Analysis

                                6.2.1 Bargaining Power of Suppliers

                                6.2.2 Bargaining Power of Consumers

                                6.2.3 Threat of New Entrants

                                6.2.4 Threat of Substitute Product and Services

                                6.2.5 Competitive Rivalry within the Industry

7. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                7.1 Market Drivers

                                7.1.1 Rise in Awareness About Fallopian Tube Cancer and Available Therapies

                                7.1.2 Increasing Health Care Expenditure

                7.2 Market Restraints

                                7.2.1 High-Cost Associated with the Surgery and Therapy

                                7.2.2 Adverse Side Effects of Treatment and Toxicity of Drugs

                7.3 Opportunities

                7.4 Key Challenges

8. Market Segmentation

                8.1 By Type of Therapy

                                8.1.1 Surgery


                                       Cytoreductive/Debulking Surgery


                                8.1.2 By Therapeutics

                                       Taxol (Paclitaxel)


                                       Pegylated liposomal doxorubicin (Caelyx)

                                       Topotecan (Hycamtin)




                8.2 By Geography

                                8.2.1 North America

                                       United States



                                8.2.2 Europe



                                       United Kingdom



                                       Rest Of Europe

                                8.2.3 Asia-Pacific




                                       Australia & New Zealand

                                       South Korea

                                       Rest of Asia-Pacific

                                8.2.4 Middle East & Africa


                                       South Africa

                                       Rest of the Middle East & Africa

                                8.2.5 South America



                                       Rest of South America

9. Competitive Landscape

                9.1 Mergers & Acquisition Analysis

                9.2 Agreements, Collaborations, and Partnerships

                9.3 New Products Launches

10. Key Players

                10.1 Amgen Inc.

                10.2 AstraZeneca

                10.3 Bayer AG

                10.4 Boehringer Ingelheim GmbH

                10.5 Bristol-Myers Squibb

                10.6 Celgene Corp.

                10.7 Eli Lilly and Company

                10.8 F. Hoffmann-La Roche AG

                *List Not Exhaustive

11. Future of the Market

Purchase Report

Our Clients Include View All

Looking to Customize Report?

Complete your payment details below

Shipping & Billing Information

Payment Information